SynthesisJournal of substance use and addiction treatment2023
Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021.
Synthesis in Journal of substance use and addiction treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Integrating Psychosocial Factors into Artificial Intelligence Models for Predicting Addiction Treatment Outcomes: A Systematic Review.European addiction research · 2026Pooled it
- Reframing Substance Misuse Prevention: a RE-AIM Analysis of Federal Infrastructure and Future Directions.Prevention science : the official journal of the Society for Prevention Research · 2026Article
- County-Level Variation in Substance Use Disorder Service Utilization by Insurance Payers and Self-Pay in the United States.The Journal of clinical psychiatry · 2026Article
- Distribution patterns of narcotic drugs, psychotropic substances, and new psychoactive substances among reported drug users in china (2014-2026): A systematic review and Meta-Analysis.Addictive behaviors reports · 2026Review
- Arrest discretion and training needs for interacting with people with substance use disorders: a qualitative secondary analysis among police recruits in Washington State.Health & justice · 2026Article
- Economic analyses of freestyle libre systems for people living with diabetes: a systematic literature review.Cost effectiveness and resource allocation : C/E · 2025Review
- What is necessary for implementation science to actually improve the state of addiction treatment and research?Journal of substance use and addiction treatment · 2025Article
- Needs and Challenges to Improve Rehabilitative Care for Parents with Substance Use Disorder - A Qualitative Study from the Expert's Perspective.Substance abuse and rehabilitation · 2025Article
- Psychopathy is a neglected public health problem.Frontiers in psychiatry · 2025Article
- Start-Up and Implementation Costs for the Trust Based Relational Intervention.Journal of prevention (2022) · 2024Article
- PERSPECTIVE: Health Economic Interests at NIMH and NIDA to Improve Delivery of Behavioral Health Services.The journal of mental health policy and economics · 2024Article
- Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe economic burden of substance use disorder (SUD) is significant, comprising costs of health care and social services, criminal justice resources, loss of productivity, and premature mortality. This study assembles and synthesizes two decades of evidence describing the benefits of SUD treatment across five main outcome domains; 1) health care utilization; 2) self-reported criminal activity by offense type; 3) criminal justice involvement collected from administrative records or self-reported; 4) productivity assessed through working hours or wages earned; and 5) social services (e.g., a day spent in transitional housing).
methodsThis review included studies if they reported the monetary value of the intervention outcomes, most commonly through a cost-benefit or cost-effectiveness framework. The search included studies from 2003 to the present day as of this writing (up to October 15, 2021). Summary cost estimates were adjusted using the US Consumer Price Index (CPI) to reflect the 12-month benefits per client in USD 2021. We followed the PRISMA methodology for study selection and assessed quality using the Checklist for Health Economic Evaluation Reporting Standards (CHEERS).
resultsThe databases yielded 729 studies after removing duplicates, and we ultimately selected 12 for review. Studies varied widely regarding analytical approaches, time horizons, outcome domains, and other methodological factors. Among the ten studies that found positive economic benefits, reductions in criminal activity or criminal justice costs represented the largest or second largest component of these benefits (range $621 to $193,440 per client).
conclusionsConsistent with previous findings, a reduction in criminal activity costs is driven by the relatively high societal cost per criminal offense, notably for violent crimes, such as aggravated assault and rape/sexual assault. Accepting the economic rationale for increased investment in SUD interventions will require recognizing that more benefits accrue to individuals by avoiding being victims of a crime than to governments through budget offsets resulting from savings in non-SUD program expenses. Future studies should explore individually tailored interventions to optimize care management, which may yield unexpected economic benefits to services utilization, and criminal activity data to estimate economic benefits across a broad range of interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.